AnHeart’s investigational medicine taletrectinib shrank tumors in more than 90% of people with ROS1+ NSCLC who were ROS1 TKI naïve in TRUST-II trial ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

ROS1 is a gene which can join (or fuse) with part of another gene. The fusion activates the ROS1 gene in a way that causes uncontrolled cancer cell growth. The gene change is called ROS1 fusion.

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation’s ...

Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib.A third ROS1 TKI approved in 2023 ...

ROS1 rearranged or ROS1-positive non-small cell lung cancer is a subtype of lung cancer that is — makes up about 1 to 2% of non-small cell lung cancer. And it's a … really interesting subtype, because ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced data from ...

Title: Crystal structure of drug-resistant ROS1 G2032R in complex with zidesamtinib, a clinical-stage ROS1 inhibitor with best-in-class potential Authors: Joseph M. Magrino * 1, Anupong ...

In ROS1-positive NSCLC patients, the drug achieved a 79% ORR in patients who had never previously been treated with a ROS1-targeting TKI, made up of 6% complete responses and 73% partial responses ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive non-small cell lung cancer (NSCLC).